Keeb kwm

Thalidomide tau qhia ua tshuaj sedative, tus neeg sawv cev immunomodulatory thiab tseem raug tshawb xyuas los kho cov tsos mob ntawm ntau cov qog nqaij hlav.Thalidomide inhibits E3 ubiquitin ligase.,uas yog CRBN-DDB1-Cul4A complex.

Kev piav qhia

Thalidomide yog thawj zaug txhawb nqa ua sedative, inhibits cereblon (CRBN), ib feem ntawm cullin-4 E3 ubiquitin ligase complex CUL4-RBX1-DDB1, nrog Kd ntawm∼250 nM, thiab muaj immunomodulatory, anti-inflammatory thiab anti-angiogenic mob qog noj ntshav.

Hauv Vitro

Thalidomide yog thawj zaug txhawb nqa raws li ib tug sedative, muaj immunomodulatory, anti-inflammatory thiab anti-angiogenic mob qog noj ntshav, thiab lub hom phiaj cereblon (CRBN), ib feem ntawm lub cullin-4 E3 ubiquitin ligase complex CUL4-RBX1-DDB1, nrog ib tug Kd ntawm∼250 nM[1]. Thalidomide (50μg / mL) muaj zog tiv thaiv qog ua haujlwm ntawm icotinib tiv thaiv kev loj hlob ntawm ob qho tib si PC9 thiab A549 hlwb, thiab cov nyhuv no cuam tshuam nrog apoptosis thiab cell migration. Tsis tas li ntawd, Thalidomide thiab icotinib inhibits EGFR thiab VEGF-R2 txoj hauv kev hauv PC9 hlwb [3].

Thalidomide (100 mg / kg, po) inhibits collagen deposition, down-regulates lub mRNA qhia theem ntawmα-SMA thiab collagen I, thiab txo cov pro-inflammatory cytokines hauv RILF nas. Thalidomide alleviates RILF los ntawm kev tsuj ntawm ROS thiab down-regulation ntawm TGF-β/Smad txoj kev nyob ntawm Nrf2 xwm txheej[2]. Thalidomide (200 mg / kg, po) ua ke nrog icotinib qhia tau hais tias muaj kev sib koom ua ke los tiv thaiv qog nqaij hlav hauv cov nas liab liab uas muaj PC9 hlwb, txo cov qog loj hlob thiab txhawb cov qog tuag [3].